Secutrelvir not checked
Shionogi · S-892216 · S-892216-LAI
FollowEvery change as it happens, and a Monday email
Trials
3 active
6 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “S-892216-LAI injection will be administered per schedule specified in the arm description.”In the company’s words, NCT07093580 on ClinicalTrials.gov
- Tested for
- COVID-19, SARS-CoV-2
- Main trialPhase 3
- “The main purpose of this study is to compare secutrelvir to placebo with respect to resolution of clinical symptoms in nonhospitalized participants with Coronavirus Disease 2019 (COVID-19) starting intervention within 48 hours of COVID-19 symptom onset.”In the company’s words, NCT07746544 on ClinicalTrials.gov
- Other names
- S-892216 · S-892216-LAI
Other drugs for COVID-19
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- VYD2311Invivyd, Inc. · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
- DAS181Ansun Biopharma, Inc. · Phase 3
Coming up3
- 31 Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- 30 Jun 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Jul 2027 | Study of Secutrelvir in Participants With COVID-19 | |
| Phase 3Recruiting | 30 Jun 2028 | A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease | |
| Phase 1Recruiting | 30 Jun 2028 | Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants | |
| Phase 2Completed | 22 Sep 2025 | A Study of S-892216 in Participants With COVID-19 | |
| Phase 1Completed | 24 Feb 2025 | A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants | |
| Phase 1Completed | 13 Feb 2026 | A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026